🇺🇸 FDA
Pipeline program

ATI 502 0.46% Topical Solution

ATI-502-AA-203

Phase 2 small_molecule terminated

Quick answer

ATI 502 0.46% Topical Solution for Alopecia Areata is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aclaris Therapeutics
Indication
Alopecia Areata
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials